Serina Therapeutics SER
NYSE SER
$1.78 +0.01 (+0.56%)
As of: Oct 22, 2026 · 2:35 PM EDT

Serina Therapeutics (SER) Non-Current Deffered Revenue (2020)

Updated

Serina Therapeutics (SER) posted Non-Current Deffered Revenue of $64,000 for Q4 2020.

Analysis

Serina Therapeutics (SER) Non-Current Deffered Revenue (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Serina Therapeutics 29.17 Mn -11.58 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 64,000.00
API Access

Serina Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=SER&period=max&api_key=YOUR_API_KEY